4.14
Alumis Inc stock is traded at $4.14, with a volume of 503.86K.
It is up +0.98% in the last 24 hours and up +38.00% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$4.10
Open:
$4.1
24h Volume:
503.86K
Relative Volume:
0.59
Market Cap:
$397.46M
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.1544
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
+7.25%
1M Performance:
+38.00%
6M Performance:
-44.65%
1Y Performance:
-66.34%
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALMS
Alumis Inc
|
4.14 | 423.08M | 0 | -238.77M | -216.62M | -26.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-25-25 | Initiated | Wells Fargo | Overweight |
Jun-10-25 | Resumed | Guggenheim | Buy |
Jan-30-25 | Initiated | Oppenheimer | Outperform |
Oct-31-24 | Initiated | Robert W. Baird | Outperform |
Oct-17-24 | Initiated | H.C. Wainwright | Buy |
Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
Jul-23-24 | Initiated | Guggenheim | Buy |
Jul-23-24 | Initiated | Leerink Partners | Outperform |
Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
What institutional investors are buying Alumis Inc. stockTop Growth Planner For Every Investor - jammulinksnews.com
When is Alumis Inc. stock expected to show significant growthStock Strategy Trend Scanner To Watch Now - jammulinksnews.com
Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - jammulinksnews.com
What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alumis (ALMS) Merges with ACELYRIN - Insider Monkey
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks
How strong is Alumis Inc. company’s balance sheetTop Growth Entry Points With Low Risk - jammulinksnews.com
What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - jammulinksnews.com
What is the dividend policy of Alumis Inc. stockUnlock your trading potential today - jammulinksnews.com
How does Alumis Inc. generate profit in a changing economyInvest confidently with professional advice - jammulinksnews.com
What are analysts’ price targets for Alumis Inc. in the next 12 monthsHigh-performance investment picks - jammulinksnews.com
What is the risk reward ratio of investing in Alumis Inc. stockAccelerated capital growth - jammulinksnews.com
Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it
What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia
Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia
Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks
Alumis initiated with an Overweight at Wells Fargo - TipRanks
What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - jammulinksnews.com
Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia
What drives Alumis Inc. stock priceUnbelievable profit margins - PrintWeekIndia
Alumis completes enrollment in lupus treatment phase 2b trial By Investing.com - Investing.com India
Alumis completes enrollment in lupus treatment phase 2b trial - Investing.com
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - The Manila Times
Alumis Inc. Completes Patient Enrollment in LUMUS Phase 2b Trial of ESK-001 for Systemic Lupus Erythematosus, Topline Data Expected Q3 2026 - Nasdaq
Major Breakthrough: 408 Patients Enrolled in Advanced Trial for New Oral Lupus Treatment - Stock Titan
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):